Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007 (Q37230344)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2009

Language	Label	Description	Also known as
English	Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007	scientific article published on February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

Europe PubMed Central

Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007 (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jennifer D Peterson

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Lawrence S Chan

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 February 2009

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Therapeutics and Clinical Risk Management

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1-7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Rituximab in refractory autoimmune bullous diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

A review of rituximab in cutaneous medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Corticosteroid-induced osteoporosis: a guide to optimum management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

How to prevent steroid induced osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Anti B cell therapy (rituximab) in the treatment of autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Rituximab in autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

9 September 2017

Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

14 September 2017

Images in clinical medicine. Pemphigus foliaceus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697541

3 September 2018

Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-lasting remission of pemphigus vulgaris treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab-induced serum sickness

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe pemphigus vulgaris treated with rituximab (Mabthera)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed response of oral pemphigus vulgaris to rituximab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19436603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19436603%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37230344&oldid=2218074719"